ASCO 2026 | Key prostate cancer trials at ASCO 2026: PROTEUS, TALAPRO-3, and A-DREAM
Andrew Armstrong, MD, MS, Duke University Medical Center, Durham, NC, provides an overview of key findings from several practice-changing trials in prostate cancer, including the PROTEUS trial (NCT03767244), which demonstrated the benefit of apalutamide plus androgen deprivation therapy (ADT), and the TALAPRO-3 trial (NCT04821622), which showed the efficacy of adding talazoparib to ADT and enzalutamide in patients with metastatic hormone-sensitive prostate cancer and homologous repair deficiencies. Additional trials of interest include the A A-DREAM trial (NCT05241860) and a Phase I trial (NCT06318273) of ABBV-969, an antibody-drug conjugate (ADC), This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
